Oral Isotretinoin for Refractory Cutaneous Pseudolymphoma: A Case Report

Authors

  • Natsinee Tangkijngamvong Division of Dermatology, Department of Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.
  • Marisa Pongprutthipan Division of Dermatology, Department of Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.

Keywords:

Cutaneous pseudolymphoma, refractory, Isotretinoin, Oral retinoids, Treatment

Abstract

Cutaneous pseudolymphoma is a benign lymphoproliferative disorder that can mimic cutaneous lymphoma's clinical and histological features. While spontaneous resolution is observed in some cases, others may exhibit a persistent or recalcitrant clinical course. In such instances, alternative therapeutic options become imperative. Here, we present a case of an 83-year-old female with erythematous plaques on the right cheek. The pathological examination confirmed the diagnosis of cutaneous pseudolymphoma, with a history of recalcitrant to various treatment modalities. Oral isotretinoin was initiated as a monotherapy, and skin lesions were resolved within a few weeks without significant adverse events. This case report aims to provide additional evidence supporting the efficacy of isotretinoin as a viable treatment option for refractory cutaneous pseudolymphoma.

References

Mitteldorf C, Kempf W. Cutaneous pseudolymphoma. Surg Pathol Clin 2017;10:455-76.

Ploysangam T, Breneman DL, Mutasim DF. Cutaneous pseudolymphomas. J Am Acad Dermatol 1998;38:877-95.

Mitteldorf C, Kempf W. Cutaneous pseudolymphoma-A review on the spectrum and a proposal for a new classification. J Cutan Pathol 2020;47:76-97.

Miguel D, Peckruhn M, Elsner P. Treatment of cutaneous pseudolymphoma: A systematic review. Acta Derm Venereol 2018;98:310-7.

Magro CM, Daniels BH, Crowson AN. Drug induced pseudolymphoma. Semin Diagn Pathol 2018;35:247-59.

Iwahashi Y, Kasa Y, Uno H, Nakada T. Pseudolymphoma successfully treated by etretinate. J Cutan Immunol Allergy 2019;2:123-4.

Huen AO, Kim EJ. The Role of Systemic retinoids in the treatment of cutaneous T-cell lymphoma. Dermatol Clin 2015;33:715-29.

Claudy AL, Rouchouse B, Boucheron S, Le Petit JC. Treatment of cutaneous lymphoma with etretinate. Br J Dermatol 1983;109:49-56.

Väkevä L, Ranki A, Hahtola S. Ten-year experience of bexarotene therapy for cutaneous T-cell lymphoma in Finland. Acta Derm Venereol 2012;92:258-63.

Zhang C, Duvic M. Retinoids: therapeutic applications and mechanisms of action in cutaneous T-cell lymphoma. Dermatol Ther 2003;16:322-30.

Downloads

Published

2023-11-15

How to Cite

Tangkijngamvong, N., & Pongprutthipan, M. (2023). Oral Isotretinoin for Refractory Cutaneous Pseudolymphoma: A Case Report. Thai Journal of Dermatology, 39(4), 94–97. Retrieved from https://he02.tci-thaijo.org/index.php/TJD/article/view/264642